-
- David M. Margolis
- University of North Carolina HIV Cure Center, Department of Medicine, and Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
-
- J. Victor Garcia
- Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
-
- Daria J. Hazuda
- Merck Research Laboratories, White Horse Junction, PA, USA.
-
- Barton F. Haynes
- Duke Human Vaccine Institute, Department of Medicine, and Department of Immunology, Duke University School of Medicine, Durham, NC, USA.
説明
<jats:title>Next steps toward curing HIV-1</jats:title> <jats:p> Since the discovery of HIV-1 more than 30 years ago, prevention and treatment strategies have dominated the research agenda. More recently, however, scientists are also focusing their efforts toward finding a cure. Margolis <jats:italic>et al.</jats:italic> review an approach that involves HIV-1 latency reversal and viral clearance. The idea is to reactivate any dormant virus and coax it to produce viral proteins that the immune system can recognize. By combining a latency reversal strategy with immunotherapies, the body might be able to rid itself of all infected cells. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencemag.org/content/353/6297/362.full">362</jats:ext-link> </jats:p>
収録刊行物
-
- Science
-
Science 353 (6297), aaf6517-, 2016-07-22
American Association for the Advancement of Science (AAAS)